VIRIDIAN THERAPEUTICS INC
NASDAQ: VRDN (Viridian Therapeutics, Inc.)
Last update: 12 hours ago22.00
0.07 (0.32%)
| Previous Close | 21.93 |
| Volume | 5,381,490 |
| Price / Sales | 29.87 |
| Price / Book | 4.42 |
| 52 Weeks Range |
| Operating Margin (TTM) | -130,369.45% |
| Diluted EPS (TTM) | -3.35 |
| Total Debt/Equity (MRQ) | 3.82% |
| Current Ratio (MRQ) | 19.49 |
| Operating Cash Flow (TTM) | -279.75 M |
| Levered Free Cash Flow (TTM) | -171.41 M |
| Return on Assets (TTM) | -32.62% |
| Return on Equity (TTM) | -51.95% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Viridian Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.33 |
|
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.16% |
| % Held by Institutions | 114.61% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bellevue Group Ag | 30 Jun 2026 | 6,731,909 |
| Paradigm Biocapital Advisors Lp | 30 Jun 2026 | 6,723,788 |
| Kynam Capital Management, Lp | 30 Jun 2026 | 6,453,877 |
| Fairmount Funds Management Llc | 30 Jun 2026 | 5,090,928 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |